Baird raised the firm’s price target on Praxis Precision (PRAX) to $275 from $76 and keeps an Outperform rating on the shares.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Midday Fly By: Salesforce targets $60B in revenue, TSMC reports Q3 beat
- Buy Rating Affirmed for Praxis Precision Medicines Following Positive Phase 3 Study Results
- Praxis Precision price target raised to $300 from $65 at Jefferies
- Praxis Precision price target raised to $350 from $155 at Guggenheim
- Why Is Praxis Precision Medicines (PRAX) Stock Up 155% Today?